Uroben XR 25 mg is a potent, selective beta-3 adrenoceptor agonist indicated for the symptomatic management of overactive bladder (OAB) in adult patients. It effectively addresses urgency, increased micturition frequency, and urgency incontinence, enhancing the patient’s quality of life by improving bladder storage function without interfering with normal voiding.

রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Therapeutic Class:
BPH / Urinary Retention / Urinary Incontinence

Mechanism of Action:
Uroben XR 25 mg works via a dual mechanism:

• Direct effect on bladder smooth muscle: Activates beta-3 adrenoceptors, increasing cyclic adenosine monophosphate (cAMP) levels, leading to relaxation of the detrusor muscle during the bladder storage phase.

• Sensory modulation: Influences the sensory nervous system, enhancing bladder capacity and reducing involuntary contractions.

During urine storage, sympathetic stimulation predominates, and beta-3 adrenoceptor activation relaxes the bladder. In the voiding phase, parasympathetic control predominates, and Uroben XR 25 mg does not interfere with normal bladder contraction, maintaining proper voiding.

Pharmacology:

• In preclinical studies, Uroben XR 25 mg increased mean voided volume, reduced non-voiding contractions, and decreased voiding frequency in both rat and monkey models.

• It demonstrated a favorable safety profile, with no significant effects on voiding pressure or residual urine.

Indications:

• Symptomatic treatment of overactive bladder (OAB) in adults.

• Management of urgency, frequency, and urgency incontinence.

Dosage & Administration:

• Adults (including elderly): Start with 25 mg once daily, with or without food. Depending on response and tolerability, the dose may be increased to 50 mg once daily.

• Renal or Hepatic Impairment: For severe renal impairment (ClCr 15–29 mL/min) or moderate hepatic impairment (Child-Pugh B), do not exceed 25 mg daily. Not recommended in end-stage renal disease or severe hepatic impairment.

• Swallow tablets whole; do not chew, divide, or crush.

Drug Interactions:

• Strong CYP3A or P-gp inhibitors may increase exposure; dose adjustment recommended in certain populations.

• Uroben XR 25 mg is a moderate CYP2D6 inhibitor; caution with narrow therapeutic index CYP2D6 substrates (e.g., metoprolol, desipramine).

• Weak P-gp inhibition may increase digoxin levels; monitor accordingly.

• No clinically significant interactions observed with solifenacin, tamsulosin, warfarin, metformin, or combined oral contraceptives.

  রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Contraindications:

• Hypersensitivity to Uroben XR 25 mg or any excipients.

• Severe uncontrolled hypertension (systolic ≥180 mmHg and/or diastolic ≥110 mmHg).

Side Effects:

• Common: Tachycardia, urinary tract infections.

• Serious (rare): Atrial fibrillation.

Precautions:

• Monitor blood pressure during treatment, especially in hypertensive patients.

• Use with caution in patients with bladder outlet obstruction or those on antimuscarinic therapy.

• Not recommended in pregnancy or lactation due to potential reproductive toxicity.

Overdose Management:

• Symptoms: Increased pulse rate, palpitations, elevated blood pressure.

• Treatment: Supportive and symptomatic; monitor cardiovascular parameters.

Storage Conditions:

• Store in a cool, dry place, protected from light.